270 related articles for article (PubMed ID: 1730087)
1. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
Collen D; Lijnen HR; Bulens F; Vandamme AM; Tulinsky A; Nelles L
J Biol Chem; 1990 Jul; 265(21):12184-91. PubMed ID: 2115513
[TBL] [Abstract][Full Text] [Related]
3. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
[TBL] [Abstract][Full Text] [Related]
4. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
[TBL] [Abstract][Full Text] [Related]
5. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
[TBL] [Abstract][Full Text] [Related]
6. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/functional domains.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
J Biol Chem; 1990 Apr; 265(10):5677-83. PubMed ID: 2156824
[TBL] [Abstract][Full Text] [Related]
9. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
Vaughan DE; Declerck PJ; Van Houtte E; De Mol M; Collen D
Thromb Haemost; 1992 Jul; 68(1):60-3. PubMed ID: 1514173
[TBL] [Abstract][Full Text] [Related]
10. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates.
Holvoet P; Dewerchin M; Stassen JM; Lijnen HR; Tollenaere T; Gaffney PJ; Collen D
Circulation; 1993 Mar; 87(3):1007-16. PubMed ID: 8443877
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
[TBL] [Abstract][Full Text] [Related]
12. Deletion of residues K296-G302 from the slowly-cleared tissue-type plasminogen activator t-PA del (G) leads to partial loss of plasminogen activating activity.
Dodd I; Browne MJ; Chapman CG; Cronk D; Hastwell C; Wilson S; Robinson JH
Biologicals; 1993 Sep; 21(3):269-74. PubMed ID: 8117440
[TBL] [Abstract][Full Text] [Related]
13. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo.
Dewerchin M; Lijnen HR; Stassen JM; De Cock F; Quertermous T; Ginsberg MH; Plow EF; Collen D
Blood; 1991 Aug; 78(4):1005-18. PubMed ID: 1831057
[TBL] [Abstract][Full Text] [Related]
14. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Lu HR; Lijnen HR; Stassen JM; Collen D
Blood; 1991 Jul; 78(1):125-31. PubMed ID: 1906351
[TBL] [Abstract][Full Text] [Related]
15. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
17. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
Collen D; Lijnen HR; Vanlinthout I; Kieckens L; Nelles L; Stassen JM
Thromb Haemost; 1991 Feb; 65(2):174-80. PubMed ID: 1905070
[TBL] [Abstract][Full Text] [Related]
18. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
